Your Health, We Care
ARROW research shows that pralsetinib has excellent anti-tumor activity and controllable safety in RET fusion positive NSCLC patients. The research results have been published in top international academic journals such as Lancet Oncol and Ann Oncol.
Pralsetinib has been unanimously recommended by authoritative guidelines such as NCCN and ESMO for the treatment of advanced NSCLC patients with RET fusion.
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
